

1 **GWAS of ~30,000 samples with bone mineral density**
2 **at multiple skeletal sites and its clinical relevance on**
3 **fracture prediction, genetic correlations and**
4 **prioritization of drug targets**

5

6 Yu Qian^{1,2,3#}, Jiangwei Xia^{4#}, Pingyu Wang^{5#}, Chao Xie⁶, Hong-Li Lin⁷, Gloria Hoi-

7 Yee Li⁸, Cheng-Da Yuan⁹, Mo-Chang Qiu¹⁰, Yi-Hu Fang¹⁰, Chun-Fu Yu¹¹, Xiang-

8 Chun Cai¹¹, Saber Khederzadeh^{1,2,3}, Pian-Pian Zhao^{1,2,3}, Meng-Yuan Yang^{1,2,3}, Jia-

9 Dong Zhong^{1,2,3}, Xin Li^{1,2,3}, Peng-Lin Guan^{1,2,3}, Jia-Xuan Gu^{1,2,3}, Si-Rui Gai^{1,2,3},

10 Xiang-Jiao Yi^{1,2,3}, Jian-Guo Tao^{1,2,3}, Xiang Chen^{1,2,3}, Mao-Mao Miao^{1,2,3}, Guo-Bo

11 Chen¹², Lin Xu⁵, Shu-Yang Xie⁵, Geng Tian⁵, Hua Yue¹³, Guangfei Li¹⁴, Wenjin

12 Xiao¹⁴, David Karasik¹⁵, Youjia Xu¹⁴, Liu Yang¹⁶, Ching-Lung Cheung¹⁷, Fei

13 Huang⁵, Zhenlin Zhang¹³, Hou-Feng Zheng^{1,2,3*}

14

15 ¹The affiliated Hangzhou first people's hospital, School of Medicine, Westlake

16 University, Hangzhou, Zhejiang, China

17 ²Diseases & Population (DaP) Geninfo Lab, Westlake Laboratory of Life Sciences

18 and Biomedicine, Hangzhou, Zhejiang, China

19 ³ Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, China;

20 ⁴Department of Neurology, Xuanwu Hospital, National Center for Neurological

21 Disorders, Capital Medical University, Beijing, China

- 1 ⁵WBBC Shandong Center, Binzhou Medical University, Yantai, Shandong, China
- 2 ⁶Institute of Science and Technology for Brain-Inspired Intelligence, Fudan
- 3 University, Shanghai, China
- 4 ⁷School of Public Health, The University of Hong Kong, Pok Fu Lam, Hong Kong
- 5 SAR, China.
- 6 ⁸Department of Health Technology and Informatics, Faculty of Health and Social
- 7 Sciences, The Hong Kong Polytechnic University, Hong Kong, China.
- 8 ⁹Department of Dermatology, Hangzhou Hospital of Traditional Chinese Medicine,
- 9 Hangzhou, Zhejiang, China
- 10 ¹⁰WBBC Jiangxi Center, Jiangxi Medical College, Shangrao, Jiangxi, China
- 11 ¹¹Department of Orthopedic Surgery, Shangrao Municipal Hospital, Shangrao,
- 12 Jiangxi, China
- 13 ¹²Clinical Research Institute, Zhejiang Provincial People's Hospital, People's
- 14 Hospital of Hangzhou Medical College, Hangzhou, China
- 15 ¹³Department of Osteoporosis and Bone Disease, Shanghai JiaoTong University
- 16 Affiliated Six People's Hospital, Shanghai, China.
- 17 ¹⁴Department of Orthopaedics, Second Affiliated Hospital of Soochow University,
- 18 Osteoporosis Research Institute of Soochow University, Suzhou, Jiangsu, China.
- 19 ¹⁵Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
- 20 ¹⁶Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical
- 21 University, Xi'an, Shaanxi, China

1 ¹⁷Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine,

2 The University of Hong Kong, Hong Kong, China.

3

4 #These authors contributed equally

5 *Correspondence: zhenghoufeng@westlake.edu.cn (H.-F.Z.)

6

7

1 **Abstract**

2 We conducted genome-wide association studies (GWAS) of dual-energy X-ray
3 absorptiometry (DXA)-derived bone mineral density (BMD) traits at 11 skeletal
4 sites, within over 30,000 European individuals from the UK Biobank. A total of 92
5 unique and independent loci were identified for 11 DXA-derived BMD traits and
6 fracture, including five novel loci (harboring genes such as *ABCA1*, *CHSY1*,
7 *CYP24A1*, *SWAP70*, and *PAX1*) for six BMD traits. These loci exhibited evidence of
8 association in both males and females, which could serve as independent replication.
9 We demonstrated that polygenic risk scores (PRSs) were independently associated
10 with fracture risk. Although incorporating multiple PRSs (metaPRS) with the
11 clinical risk factors (i.e., the FRAX model) exhibited the highest predictive
12 performance, the improvement was marginal in fracture prediction. The metaPRS
13 were capable of stratifying individuals into different trajectories of fracture risk, but
14 clinical risk factors played a more significant role in the stratification. Additionally,
15 we uncovered genetic correlation and shared polygenicity between head BMD and
16 intracranial aneurysm. Finally, by integrating gene expression and GWAS datasets,
17 we prioritized genes (e.g. *ESR1* and *SREBF1*) encoding druggable human proteins
18 along with their respective inhibitors/antagonists. In conclusion, this comprehensive
19 investigation revealed a new genetic basis for BMD and its clinical relevance on
20 fracture prediction. More importantly, it was suggested that head BMD was
21 genetically correlated with intracranial aneurysm. The prioritization of genetically
22 supported targets implied the potential repurposing drugs (e.g. the n-3 PUFA
23 supplement targeting *SREBF1*) for the prevention of osteoporosis.

24

25 **Keywords:** bone mineral density, drug targets, fracture, genome-wide association
26 study, intracranial aneurysm, omics, polygenic risk scores.

1 **Introduction**

2 Osteoporosis, a systemic skeletal disease characterized by decreased bone mass and
3 micro-structural damage ^{1,2}, has a global prevalence of 18.3% [95% confidence
4 interval (95% CI): 16.2%-20.7%] ³. Bone mass could be assessed by 2-dimensional
5 projectional scans with dual-energy X-ray absorptiometry (DXA), or other medical
6 imaging tools, such as quantitative computed tomography (QCT) and quantitative
7 ultrasound (QUS) ⁴. Genome-wide association studies (GWASs) and meta-analyses
8 were carried out to explore the genetic factors for bone mineral density (BMD),
9 osteoporosis, and fracture ^{1,2}. Early GWAS design only involved thousands of
10 samples and only several loci were identified ^{5,6}. The meta-analysis could enlarge
11 the sample size and statistical power, and lead to the identification of more loci ^{7,8}.
12 However, the genetic summary data, instead of individual-level genotype data, from
13 each cohort were meta-analyzed in the aforementioned studies. Recently, large-scale
14 biobanks such as the UK biobank could enable access to the individual-level
15 genotype data in hundreds of thousands of samples, and hundreds of genetic loci
16 were identified for QUS-derived BMD in these efforts ^{9,10}.

17
18 Although GWASs have been successfully conducted in the past decade, the ultimate
19 goal of genetic study is to translate the discoveries into clinical practice. Previously,
20 we have tried to summarize the clinical use of GWAS findings in the bone field,
21 such as disease prediction ¹. Lu et al developed the genetically predicted speed of
22 sound (SOS, a parameter measured by QUS) for individuals in UK Biobank by
23 common genetic variants through polygenic risk score (PRS) ¹¹. They demonstrated
24 that this score provided modestly better fracture risk prediction than some of the
25 clinical risk factors such as smoking and use of corticosteroids ¹¹. In addition, they
26 suggested that adding rare variants did not demonstrate substantially improved
27 predictive performance in a recent study ¹². The above studies took the SOS
28 measurement in the training and testing dataset, however, the SOS measurement was

1 not correlated very well with BMD¹³. Another clinical relevance of GWAS findings
2 is to infer the correlation between diseases¹. Earlier efforts have uncovered
3 numerous SNPs exhibiting pleiotropic associations with BMD and other
4 traits/diseases, such as birth weight¹⁴, type 2 diabetes¹⁵, and major depressive
5 disorder¹⁶. Finally, incorporating genetic data in drug development is warranted to
6 improve this process, because drugs with genetic support are more likely to succeed
7 in clinical trials^{17,18}.

8
9 Therefore, with the availability of DXA-derived BMD phenotypes and individual-
10 level genotype data in UK Biobank, it is an opportunity to conduct a genome-wide
11 association study at large scale individual-level genotype data and to investigate the
12 genetic basis of BMD at 11 sites (arm, femur total, femur neck, head, leg, pelvis,
13 lumbar spine, rib, and spine) and fracture (**Supplementary Figure 1**). We then build
14 a ‘multi-BMD PRS’ predictive model to improve genetic risk stratification for
15 fracture. In addition, we estimated the shared genetic architecture of BMD with
16 other common chronic diseases, including neurodegenerative, cardiovascular, and
17 autoimmune diseases. Finally, we tried to explore the potential effective and safe
18 therapeutic targets for osteoporosis.

19

20 **Results**

21 **Genetic architecture of BMD at multiple skeletal sites**

22 The overview of the study design was presented in Supplementary Figure 1.
23 Specifically, we conducted the GWAS analyses for BMD at 11 anatomic sites (i.e.,
24 arm, total femur, femoral neck, head, legs, lumbar spine, pelvis, ribs, spine, trunk,
25 and total body) and any-type fracture (**Figure 1A**) in male and female separately.
26 For each BMD trait, we then conducted meta-analyses to combine the results from
27 both genders (for BMD traits: N≈30,000; for any-type fracture: N=35,192 for cases;
28 N=317,599 for controls). The reported loci should exhibit evidence of association in

1 both males and females, which could serve as independent replication (**Figure 2 A-E**
2 **Supplementary Table 1**, and **Supplementary Table 2**). All intercept values from
3 the LD score method were close to one, revealing no obvious population
4 stratification for all GWASs (**Supplementary Table 3**). We observed that
5 approximately 25.7%~41.8% of the variance in BMD and 4.8% of the variance in
6 fracture risk could be explained by common variants across the genome (**Table 1**).
7 We then conducted conditional analyses within phenotype and identified 240 unique
8 conditional independent BMD signals (**Table 1, Figure 1B, Supplementary Table 1,**
9 **and Supplementary Figure 2-13**). After merging the physically overlapped signals
10 across BMD phenotypes (i.e., the distance between two conditional independent
11 SNVs < 500kb) into one locus, a total of 91 unique and independent BMD loci were
12 defined (**Table 1, Figure 1B and Supplementary Table 1**). We identified 8 loci for
13 fracture, 7 of which overlapped with the above BMD signals, and one of which
14 (independent SNP: rs13281992) was previously reported to be genome-wide
15 significant associated with heel BMD ¹⁰ (**Table 1, Figure 1B and Supplementary**
16 **Table 1**).

17

18 *Five loci identified for DXA-derived BMD traits*

19 Although previous GWASs have reported hundreds of loci, we still identified five
20 loci for six BMD traits that were not reported previously (**Figure 1B and Figure 2**
21 **A-E**). Among these loci, the most pleiotropic locus resided between *ABCA1* and
22 *SLC44A1* genes on chromosome 9 (**Figure 1B, Figure 2A, and Supplementary**
23 **Table 4**). SNPs (rs1039406 and rs746100) around this locus were genome-wide
24 significantly associated with five BMD sites, including the lumbar spine, femur neck,
25 femur total, pelvis, and trunk (**Figure 1B, Figure 2A, and Supplementary Table 1**).
26 The eQTL data from whole blood tissue revealed that SNP rs746100 was also
27 associated with the gene expression of *ABCA1* ($P=2.68\times 10^{-5}$) in artery tibial tissue,
28 based on the GTEx consortium (**Supplementary Table 5 and Supplementary**

1 **Figure 14**), and the genetically predicted higher *ABCA1* gene expression in whole
2 blood tissue was associated with higher BMD (**Figure 2A**). The second promising
3 locus resided between *SWAP70* and *WEE1* genes on chromosome 11 with leading
4 SNP rs10840273, showing a genome-wide significant association for leg BMD (P -
5 value= 4.52×10^{-9}) (**Figure 2B**, **Supplementary Table 1** and **Supplementary Table**
6 **4**). Whole blood eQTL data from eQTLGen identified that rs10840273 was
7 associated with the *SWAP70* gene expression ($P=2.42 \times 10^{-39}$) (**Supplementary**
8 **Table 5** and **Supplementary Figure 15**). Mesenchymal stem cell Hi-C data also
9 detected a direct interaction of the associated region with the *SWAP70* gene (FDR-
10 corrected P -value_{interaction}= 2.74×10^{-109}) (**Supplementary Table 6**). Furthermore, this
11 lead SNP showed a genome-wide significant association with circulating *SWAP70*
12 (P -value= 6.94×10^{-81}). The MR results revealed that genetically predicted higher
13 *SWAP70* gene expression and higher circulating *SWAP70* protein in whole blood
14 were significantly associated with increased leg BMD (**Figure 2B**).

15

16 Another locus surrounding rs12916774 on chromosome 15 was associated with
17 femur neck and femur total BMD (**Figure 2C** and **Supplementary Figure 16**). Both
18 eQTL data and Mesenchymal stem cell Hi-C data consistently supported the *CHSY1*
19 as a plausible candidate gene ($P=2.15 \times 10^{-53}$ for *CHSY1* eQTL in whole blood tissue
20 from eQTLGen; FDR-corrected P _{interaction}= 1.72×10^{-49} for Hi-C data)
21 (**Supplementary Table 5** and **Supplementary Table 6**). The fourth locus (lead
22 SNP: rs6013897) was an intergenic region of *CYP24A1* and *BCAS1* (**Figure 2D**,
23 **Supplementary Table 4** and **Supplementary Figure 17**). The Mesenchymal stem
24 cell Hi-C data detected a direct interaction of the associated region with the
25 *CYP24A1* gene (FDR-corrected P _{interaction}= 8.04×10^{-78}) (**Supplementary Table 6**).
26 We further prioritized *PAX1* as a potential candidate gene for rs927059, which is a
27 lead SNP for femur neck BMD (P -value= 1.87×10^{-8}) (**Figure 2E**, **Supplementary**
28 **Table 4** and **Supplementary Figure 18**). The positional and eQTL annotation

1 results consistently supported the *PAXI* as a candidate gene for rs927059 (*P*-
2 value= 4.40×10^{-6} for *PAXI* eQTL in muscle skeletal tissue from GTE_x)
3 (**Supplementary Table 4** and **Supplementary Table 5**). In summary, using multi-
4 omics datasets, we prioritized 5 potential candidate genes (i.e., *ABCA1*, *CHSY1*,
5 *CYP24A1*, *SWAP70*, and *PAXI*) to 5 novel loci (**Figure 1B**, **Figure 2 A-E**, and
6 **Supplementary Table 4-6**). The annotation results for other known loci have also
7 been shown in **Supplementary Table 4-7**.

8

9 **Polygenic risk score demonstrated marginal improvement in** 10 **fracture prediction**

11 Based on effect size derived from GWASs 11 DXA-BMD traits, heel BMD, and
12 fracture in training datasets, we selected SNPs that could achieve the best predictive
13 PRSs for fracture in the validation dataset (**Figure 3A**), resulting in 29 (for rib
14 BMD)-79292 (for head BMD) selected SNPs for different trait (**Supplementary**
15 **Table 8**). After obtaining SNPs and the effect size for each trait, we calculated the
16 corresponding PRS for each participant in the test dataset (**Figure 3A**). The
17 metaPRS was generated by integrating these 13 individual PRSs using stepwise Cox
18 regression in the validation cohort dataset (**Figure 3A**), with estimates for each
19 single PRS contained in the best-performing model (**Supplementary Table 9**). The
20 association of metaPRS with fracture incidence was largely independent of the
21 traditional risk factors (**Supplementary Table 10**). As illustrated in **Figure 3B**,
22 most individual PRSs showed significant associations with fracture risk in the test
23 cohort dataset ($P \leq 0.05$) after adjusting for age, sex, obesity, smoking, alcohol,
24 glucocorticoid medicine use, BMD, and population stratification. However, these
25 PRSs exhibited similar effect estimates for fracture risk, with the metaPRS
26 displaying the most prominent association [HR: 1.134, 95% confidence interval (CI)
27 1.098-1.172, $P = 4.15 \times 10^{-14}$] (**Figure 3B**). Furthermore, we observed a more
28 marked gradient of fracture risk across quintiles of metaPRS (HR=1.364, 95%

1 CI=1.243-1.498) than fracture PRS (HR=1.177, 95% CI=1.077-1.287) in the top
2 quartile vs. the bottom quartile (**Supplementary Table 11**).

3

4 By including only clinical factors such as age, sex, BMI, smoking, alcohol use, and
5 glucocorticoid use (the FRAX model), we observed limited predictive performance
6 of this model (C-statistic=0.608, sd=0.005) (**Figure 3C** and **Supplementary Table**
7 **12**). We found that adding BMD to the FRAX model increased the C-statistic from
8 0.608 to 0.637 (difference, 4.77%, $P=3.77\times 10^{-21}$) (**Figure 3C** and **Supplementary**
9 **Table 12**). However, the addition of various PRS to the FRAX-BMD model did not
10 substantially improve the C-statistic (**Figure 3C** and **Supplementary Table 12**).
11 Incorporating metaPRS into the FRAX-BMD model resulted in the highest C-
12 statistic (C-statistics = 0.641), with a C-statistic change of 0.63% ($P=0.003$),
13 compared with the FRAX-BMD model (**Figure 3C** and **Supplementary Table 12**).
14 By utilizing the optimal cutoff point from the FRAX-BMD metaPRS model as the
15 threshold, the combination of metaPRS and FRAX-BMD model yielded a moderate
16 improvement in net reclassification improvement (NRI=1.66%, 95% CI 0.7%-2.62%;
17 the continuous NRI: 9.15%, 95% CI 6.39%-11.91%) (**Supplementary Table 13**).

18

19 We further assessed how the interplay of the metaPRS and clinical risk factors
20 impact the fracture risk. Firstly, we found that the cumulative incidence for fracture
21 events was 4.63% for individuals with low polygenic risk (bottom quintiles of the
22 metaPRS) and 7.58% among those with high polygenic risk (top quintiles of the
23 metaPRS), suggesting that metaPRS could stratify individuals into different
24 trajectories of fracture risk (**Supplementary Figure 19**). Similar results were
25 observed in both sexes, with women having higher HR (**Supplementary Table 11**)
26 and higher cumulative risk (**Supplementary Figure 20** and **Supplementary Figure**
27 **21**). Although we observed significant gradients in the 10-year probability of
28 fracture occurrence across metaPRS categories within each clinical risk strata

1 (Figure 3D), the clinical risk factors played more important role in the stratification.
2 For example, among participants with low clinical risk, the 10-year probability of
3 fracture occurrence for those with high genetic risk (2.40% sd=0.59%) was yet
4 lower than the participants with median clinical risk but low genetic risk (3.26%,
5 sd=0.69%) (Figure 3D). And the 10-year probability of fracture of the participants
6 at high clinical risk with low genetic risk (5.81%, sd=1.27%) had already exceeded
7 the 10-year probability in fracture cases only (5.35%, sd=2.63%) (Figure 3D). The
8 lifetime risk of incident fracture was higher in each stratum than the 10-year
9 probability (Figure 3D). Participants at high clinical risk with median/high genetic
10 risk demonstrated lifetime probabilities of 10.18% and 12.08%, surpassing the
11 intervention treatment threshold of 10% for a major fracture at age 55 years when
12 treatment should be recommended ¹⁹(Figure 3D).

13

14 **The shared genetic architecture of head BMD and intracranial** 15 **aneurysm**

16 We further estimated the shared genetic architecture of DXA-BMD at 11 sites with
17 other 13 common chronic diseases, including neurodegenerative diseases,
18 cardiovascular diseases and autoimmune diseases (Supplementary Table 14). First
19 of all, we tested the pair-wise correlation between the BMD traits. It is suggested
20 that there were the weakest correlations for head BMD with other BMD traits in
21 both phenotypic and genetic correlation analyses, although all pairs exhibited
22 statistically significant phenotypic correlation (Figure 4A). In the 143 BMD-disease
23 pairs (11 BMD traits × 13 diseases), we only observed a statistically significant
24 inverse genetic correlation of head BMD with intracranial aneurysm (IA) ($r_g=-0.188$,
25 $se=0.055$, FDR-corrected $P=0.0096$), while the genetic correlations with other 12
26 common chronic diseases were not significant (FDR-corrected $P>0.05$) (Figure 4B
27 and Supplementary Table 14). Furthermore, no significant genetic correlation was
28 observed for the remaining 10 DXA-BMD traits with IA (FDR-corrected $P>0.05$)

1 (Figure 4B and Supplementary Table 14). Compared to the specificity of observed
2 genetic correlation, there was a similar MiXeR estimated polygenic overlap between
3 head BMD and IA. 29.36% (N=114, SD=15) of the 390 head-BMD influencing
4 variants were also predicted to influence IA (Figure 4C and Supplementary Table
5 15). By employing the conjFDR method, we identified four genomic loci jointly
6 associated with head BMD and IA (Figure 4D, Figure 4E, and Supplementary
7 Table 16). Intriguingly, 3 of the 4 lead SNPs (rs72560793, rs10958404, rs11187838)
8 had the opposite effect direction, consistent with the moderate inverse genetic
9 correlation between head BMD and IA (Figure 4E, and Supplementary Table 16).
10 Notably, two of the four loci demonstrated strong evidence of colocalization
11 ($H_4 > 0.5$), suggesting the presence of shared causal variants between head BMD and
12 IA (H_4 : 0.809 for rs10832558 within *SOX6*; H_4 : 0.581 for rs11187838 within
13 *PLCE1*) (Supplementary Table 17). Genes mapped to these shared loci were
14 enriched for biological processes and cellular components related to the skeletal
15 systems (e.g., positive regulation of chondrocyte differentiation) and vascular
16 smooth muscle (i.e., regulation of Ras protein signal transduction) (Supplementary
17 Table 18).

18

19 **Prioritization of drug targets**

20 Subsequently, by integrating the druggable genome, gene expression, and GWAS
21 datasets, we aimed to identify the genetically supported potential therapeutic targets
22 for osteoporosis, emulating exposure to corresponding medications. Utilizing drug
23 target information from the ChEMBL database (release 29), we included a total of
24 3,329 druggable genes for subsequent analyses. Next, we employed eQTL data from
25 muscle (including 791 druggable genes), artery tibial (917 druggable genes), and
26 whole-blood tissue (845 druggable genes from GTEx; 2104 druggable genes from
27 eQTLGen) to test the association with BMD through mendelian randomization
28 approach. We observed statistically significant associations between genetically

1 predicted expression of 15 genes and DXA-BMD (FDR-corrected $P < 0.05$)
2 (**Supplementary Table 19**). Among these, genetically predicted expressions of 4
3 genes (*CCRI*, *ESRI*, *NCORI* and *SREBF1*) were associated with at least two DXA-
4 BMD traits with consistent direction, providing robust MR evidence for the genes
5 (**Figure 5A, 5B** and **Supplementary Table 19**). For these four genes, genetically
6 predicted *ESRI* gene expression showed negative associations with 9 DXA-BMD
7 traits (**Figure 5A** and **5B**). There were positive associations of genetically predicted
8 *NCORI* gene expression with head BMD and total BMD, while negative
9 associations were found for *SREBF1* and *CCRI* gene expressions (**Figure 5A** and
10 **5B**). To assess whether the genetic association between these gene expressions and
11 phenotypes shared the same causal variant, we conducted colocalization analyses of
12 the genes with DXA-BMD traits. We discovered that eQTLs in whole blood tissue
13 for 3 genes (i.e., *SREBF1*, *NCORI* and *CCRI*) colocalized with DXA-BMD loci
14 ($H4 > 0.5$), reinforcing the evidence for these genes as drug targets for DXA-BMD
15 (**Figure 5C** and **Supplementary Table 20**). Considering the observed negative
16 association between *SEEBF1* and *CCRI* gene expression and BMD
17 (**Supplementary Table 19**), there were relevant inhibitors/antagonists that have
18 been approved or under investigation that present possible repurposing opportunities
19 for osteoporosis treatment. Specifically, SEBF1 could be targeted using Doconexent
20 (inhibitor) and Omega-3 fatty acids (inhibitor), while CCR1 could be targeted using
21 CCX354-C (antagonist) (**Figure 5D**).

22

23 Discussion

24 In this study, we first conducted the large-scale GWASs of DXA-BMD at 11
25 skeletal sites, and identified 91 unique and independent loci associated with at least
26 one phenotype, including five previously unreported BMD loci for six BMD traits
27 (i.e., *ABCA1*, *CHSY1*, *CYP24A1*, *SWAP70* and *PAX1*). These novel loci exhibited
28 evidence of association in both male and female, which could serve as independent

1 replication. Additionally, the incorporation of multiple PRSs (metaPRS) with the
2 clinical risk factors (i.e., the FRAX model) exhibited the highest predictive
3 performance, however, the improvement was marginal in fracture prediction.
4 Although the metaPRS could stratify individuals into different trajectories of
5 fracture risk, the clinical risk factors played a more important role in the
6 stratification. We further estimated the shared genetic architecture of DXA-BMD at
7 11 sites with other common chronic diseases, including neurodegenerative diseases,
8 cardiovascular diseases and autoimmune diseases, and we only uncovered genetic
9 correlation and shared polygenicity between head BMD and intracranial aneurysm.
10 And the gene *PLCE1* might play important roles in the shared polygenicity. Finally,
11 by integrating the gene expression and GWAS datasets, we prioritized drug targets
12 (e.g. *ESRI*, *SREBF1*, *CCR1* and *NCOR1*) within the druggable genomic genes along
13 with their respective inhibitors/antagonists.

14

15 Although previous GWAS have identified hundreds of association signals ^{1,2}, we
16 considered reporting five loci in this study when the associated SNPs improved at
17 least two orders of magnitude of significance compared to the most significant SNPs
18 within the region (position-of-reported-SNP±250 kb) in any of the previous BMD
19 GWASs. For example, in our study, the locus (rs746100) near *ABCA1* was
20 associated with five BMD traits, including the lumbar spine, femur neck, total femur,
21 pelvis, and trunk with the smallest *P*-value at 1.64×10^{-9} . By looking back at the
22 meta-analysis of GWAS in a relatively large sample size ($N \sim 30,000$), the SNP
23 rs1831554 within this locus had a marginal significance for femur neck ($P = 9.94 \times 10^{-5}$)
24 and lumbar spine ($P = 1.41 \times 10^{-4}$) BMD ⁸. The pair-wise LD of the two lead SNPs
25 was 0.0005. In our study, we used the individual-level genotype data within ~30,000
26 samples, the sample size was as large as the GWAS meta-analysis of summary
27 statistic data ⁸, but the association significance improved greatly. It is suggested that
28 the association analysis performed in individual-level genotype data could enable a

1 more comprehensive power to control various factors, such as population structure,
2 covariates, and phenotype definitions ²⁰. Another example was the locus near the
3 *CHSY1* gene, this locus showed marginal significance (P -value= 2.30×10^{-5} for
4 rs3784491) in the largest-scale GWAS to date for QUS-derived heel BMD ¹⁰, the
5 sample size was more than ten times compared to our study, however, the SNP
6 rs12916774, with very low LD with rs3784491 (LD $r^2=0.005$), was found to be
7 genome-wide significantly associated with femur neck BMD in our study
8 ($P=2.14\times 10^{-9}$). It should be noted that QUS-derived BMD primarily reflected the
9 bone mass at the heel calcaneus and exhibited limited correlation (0.5~0.65) with
10 DXA-derived BMD at the spine and hip ²¹. Additionally, we confirmed the
11 *ZIC1/ZIC4* locus for head BMD ($P=2.19\times 10^{-8}$) which was reported in a very recent
12 GWAS meta-analysis ²².

13

14 One of the potential applications of genetic data is disease prediction ¹. Lu et al
15 calculated the genetically predicted speed of sound (SOS, measured by quantitative
16 ultrasound at the heel) for individuals in the UK Biobank and assessed the predictive
17 performance of this score ¹¹. In this study, we used three independent datasets and
18 generated PRSs for the DXA-derived BMD at multiple skeleton sites. Our results
19 indicated that PRSs had robust associations with incident fracture, even after
20 adjusting for the related clinical risk factors such as age, sex, obesity, smoking,
21 alcohol, glucocorticoid use and BMD, suggesting the independent contribution to
22 the susceptibility of fracture. We further built metaPRS by combining multiple PRSs
23 for DXA-BMD, heel BMD, and fracture to evaluate the potential of PRSs on
24 fracture prediction. As expected, the metaPRS showed a larger effect size on
25 fracture risk than fracture PRS. This improvement could be attributed to that the
26 genetic component of this metaPRS captured the majority of the genetic basis of
27 fracture. At baseline, we included the FRAX factors ²³ in the prediction model, and
28 only limited predictive performance was observed just as before ²⁴. We observed an

1 increased C-statistic when incorporating BMD into the FRAX model. However, the
2 addition of various PRS to the FRAX-BMD model did not substantially improve the
3 C-statistic, suggesting that the predictive performance of PRS did not perform as
4 well as BMD measurement itself. Additionally, the probability of fracture
5 occurrence for those with low clinical risk and high genetic risk was yet lower than
6 the participants with median clinical risk but low genetic risk, suggesting that the
7 clinical risk factors played a more important role in the stratification. Lu et al
8 suggested that the predictive performance of genetically determined SOS surpassed
9 single clinical risk factor such as smoking, corticosteroids use and falls etc ¹¹, but
10 they did not test the combination of these risk factors. Consistently, the
11 predictive performance of PRS would not outperform BMD ¹¹.

12

13 Clinically, intracranial aneurysm (IA) is characterized by a bulge or distention of an
14 artery in the brain due to weakness and inelasticity of the vessel wall ²⁵. The
15 disruption of the extracellular matrix (ECM) has been proposed as a contributing
16 factor in the pathophysiology of IA ²⁶. The ECM is also a salient feature of bone
17 tissue. Bone ECM, containing minerals deposited on highly crosslinked collagen
18 fibrils, dynamically interacts with osteoblasts and osteoclasts to regulate the process
19 of bone regeneration ²⁷. Given the shared histological basis of bone and vessel, the
20 genetic correlation analysis in this study suggested that higher head BMD would
21 associated with a lower risk of IA. This genetic association was supported by an
22 epidemiological study that the IA risk was increased in patients with BMD in middle
23 and lower tertiles compared with patients with BMD in higher tertile ²⁸. Further,
24 with conditional false discovery rate approach ²⁹, we identified four shared signals,
25 emphasizing the pleiotropic effect underlying BMD and IA. Two of them
26 demonstrated evidence of colocalization (rs10832558 near *SOX6* and rs11187838
27 near *PLCE1*). The SNP rs10832558 was at the same effect direction for head BMD
28 and IA, which was not consistent with the inverse genetic correlation. Here, we

1 highlighted the variant rs11187838 shared by BMD and IA with opposite effect
2 direction, which had not been detected by both previous single-trait analyses. This
3 SNP was mapped to the *PLCE1* gene, encoding the enzyme phospholipase C
4 epsilon-1. This enzyme could stimulate the Ras and mitogen-activated protein
5 kinase (MAPK) signaling pathway through the regulation of heterotrimeric G
6 protein Galpha³⁰. Ras signaling stimulated the proliferation of immature
7 osteoprogenitor cells to increase the number of osteoblastic descendants in a cell-
8 autonomous fashion³¹. Additionally, the activation of Ras/MAPK signals could
9 stimulate the migration and proliferation of vascular smooth muscle cells through
10 fibronectin³². These synthetic vascular smooth muscle cells could secrete large
11 amounts of ECM components, including collagen, elastin, and matrix
12 metalloproteinase, causing vascular ECM remodeling³³. All these results suggested
13 that *PLCE1* might play important roles in the shared polygenicity between BMD and
14 IA. Finally, we did not observe genetic correlations between BMD and other
15 diseases in our study. As the global genetic correlation represented the average of
16 genome-wide shared association, the nonsignificant global correlation might be due
17 to opposing directions at different genomic regions³⁴.

18

19 Several pharmacological agents were available to osteoporosis patients, either by
20 reducing bone resorption such as bisphosphonate and denosumab, or by stimulating
21 bone formation such as teriparatide and abaloparatide³⁵. The fruitful GWAS
22 discoveries in the bone field have proven useful in identifying compounds suitable
23 for drug repurposing³⁶. One possible approach is to use genetic variants associated
24 with the expression level of a gene encoding druggable human protein to proxy the
25 lifelong exposure to a medication targeting corresponding gene production^{37,38}. This
26 Mendelian randomization (MR) approach could mimic a randomized controlled trial
27 to cost-effectively predict the treatment response of a drug^{37,38}. In this study, by
28 using GWAS data and eQTL data, we prioritized several drug targets for

1 osteoporosis such as ESR1 and SREBF1, etc. The estrogen hormone therapy,
2 targeting ESR1 protein, was an old-fashioned treatment for osteoporosis and was
3 rarely used nowadays because of the adverse side effects such as cardiovascular
4 conditions and cancer ³⁹. The SREBF1 we would highlight here was the target of
5 Doconexent (a high-docosahexaenoic acid supplement) and Omega-3 fatty acids.
6 Daily marine omega-3 supplementation had been widely recommended in the
7 prevention of adverse coronary events ^{40,41}. However, the effect of this kind of fatty
8 acid on bone health is controversial. For example, a meta-analysis of 23 randomized
9 controlled trials did not show any significant effect of n-3 PUFA supplementation on
10 BMD at any body's part ⁴². Nevertheless, when subgroup analyses were performed,
11 it was observed that the impact of n-3 PUFA supplementation on BMD varied
12 across different regions ⁴². Specifically, individuals from Eastern countries exhibited
13 higher BMD at the lumbar spine and femoral neck following n-3 PUFA
14 supplementation, in comparison to individuals from Western countries ⁴². However,
15 another systematic review and meta-analysis of randomized controlled trials
16 suggested that n-3 PUFAs might have a beneficial effect on bone health, especially
17 for postmenopausal women ⁴³. In our study, we revealed a negative association
18 between *SREBF1* gene expression and BMD. Previous studies suggested that the
19 supplement of omega-3 polyunsaturated fatty acid negatively regulated SREBF1
20 ^{44,45}. And decreased expression of the *SREBF1* gene could inhibit osteoclast
21 formation and bone resorption activity by decreasing NF-κB signaling ⁴⁶. Therefore,
22 we hypothesized that the n-3 PUFA supplementation might be effective for the
23 prevention of osteoporosis. For CCR1 antagonist, BMS-817399 failed in Phase 2,
24 double-blind, placebo-controlled clinical trial ⁴⁷, while another CCR1 antagonist
25 (CCX354-C) has shown a good safety and tolerability profile and evidence of
26 clinical activity in rheumatoid arthritis in Phase II trials (NCT01242917) ⁴⁸. Previous
27 animal study have shown that the activation of CCR1 leads to the formation of
28 osteolytic lesions through the regulation of CCL3 ⁴⁹.

1

2 In conclusion, we conducted large-scale GWASs of DXA-derived BMD traits and
3 identified novel signals that will likely provide new insights into the biological
4 mechanism of osteoporosis. We demonstrated that although PRSs were
5 independently associated with fracture risk, the predictive performance improved
6 marginally compared to the clinical risk factors. Additionally, we uncovered a
7 genetic correlation between head BMD and IA, and the joint associated genes such
8 as *PLCE1* might play important roles in the shared genetic basis. Finally, the
9 prioritization of genetically-supported targets implied the potential repurposing
10 drugs (for example the n-3 PUFA supplements targeting SREBF1) for the
11 prevention of osteoporosis.

12

1 **Materials and methods**

2 **Source of the phenotypes and quality control of the genotype**

3 As we used before ⁵⁰⁻⁵², the individual-level data from the UK biobank (Application
4 41376) was used for discovery analyses. The UK Biobank is a cohort of roughly
5 ~500,000 participants aged 40-69 years, of which, 487,409 participants were
6 genotyped with the UK Biobank Axiom or UK UKBiLEVE Array, and then
7 imputed by the 1000 Genomes Project (Phase 3) reference panel ^{53,54}. Ethics
8 approval for the UK Biobank research was obtained from the North West
9 Multicentre Research Ethical Committee, and all participants provided informed
10 consent (original ethics committee approval number: 21/NW/0157). In this study,
11 we extracted BMD traits measured by dual-energy X-ray (DXA) from 11 anatomical
12 sites (i.e., arm, total femur, femoral neck, head, legs, lumbar spine, pelvis, ribs, spine,
13 trunk, and total body) and fracture as phenotypes (**Figure 1A** and **Supplementary**
14 **Table 21**). The fracture cases were defined as participants with the diagnosis of any
15 site of fracture (except fractures with known primary diseases and those with
16 diseases that might affect bone health) (**Supplementary Table 21**). To minimize the
17 population stratification bias, we further excluded participants who were not of
18 European ancestry (**Supplementary Table 21**), and those who had a kinship with
19 any participants. For quality control of genotype data, the variants were excluded if
20 the minor allele frequency (MAF) < 0.01, imputation info score < 0.3, missing
21 genotype rates > 0.05, and *P*-value for Hardy–Weinberg equilibrium test < 1×10^{-6} .
22 After the quality control, a total of 5,996,792 imputed variants and around ~30,000
23 participations (**Figure 1A** and **Table 1**) remained for BMD GWAS analysis, as well
24 as 352,791 participants (N=35,192 for cases; N=317,599 for controls) for fracture
25 GWAS (**Figure 1A** and **Table 1**).

26

1 **Genetic association analysis of BMD and fracture**

2 To identify the genetic variants associated with BMD at a genome-wide significant
3 level ($P \leq 5 \times 10^{-8}$), we conducted the GWAS analyses on BMD traits at 11 skeletal
4 sites. For BMD at each site, the values (g/cm^2) were stratified by sex, and then
5 adjusted for age, age², weight, menopause status (only for females), and first 5
6 principal components using linear regression. The standardized residuals (mean=0
7 and sd=1) in males and females (i.e., standardized BMD) were used in the GWAS
8 analyses. The associations between genetic variants with phenotypes (i.e.,
9 standardized-BMD at 11 skeletal sites) were analyzed using the PLINK software
10 (<http://www.cog-genomics.org/plink2/>). We then combined the summary statistics
11 of the two sexes by an inverse variance weighted fixed effects meta-analysis, using
12 the METAL software⁵⁵. We also analyzed the association between genetic variants
13 and fracture risk, adjusting for sex, age, weight, and the first 5 principal components
14 using the PLINK software. The lead SNP of novel loci with P -value from sex-
15 stratified GWASs less than 0.05 were considered to be replicated.

16

17 **Identification of statistical independence and novel loci**

18 The conditional independent signals for each BMD trait (between-sex meta-analysis)
19 were defined using the conditional and joint (COJO; gcta --cojo-slct) analysis⁵⁶.
20 10,000 randomly selected unrelated white British individuals from the UK Biobank
21 were used as linkage disequilibrium (LD) references. The conditional independent
22 SNV for each signal was defined as the SNV with both P -value for original GWAS
23 and P -value for COJO joint analyses less than 5×10^{-8} . Among these independent
24 signals, the association was classified into the “novel” signal if all SNPs within one
25 signal (conditional independent SNV \pm 250 kb) have not been reported to be
26 significantly associated with BMD ($P < 1 \times 10^{-6}$) in previous BMD GWASs^{8,10,57}.
27 Across 11 BMD traits, the identified conditional independent significant SNVs were
28 merged into one locus if they were closely located to each other (<500 kb), leaving

1 the SNP with the smallest P -value as the lead SNP. The pleiotropic genomic locus
2 was defined as a genomic locus containing multiple conditional independent signals
3 for different BMD traits.

4

5 **Variant annotation**

6 We then used the ANNOVAR software⁵⁸, and Functional Mapping and Annotation
7 of Genome-wide Association Studies (FUMA, <https://fuma.ctglab.nl/>)⁵⁹, as well as
8 Online Mendelian Inheritance in Man database (OMIM, <http://omim.org/>)⁶⁰, to
9 obtain functional annotation for conditional independent significant SNVs.
10 Specifically, these SNVs were first physically annotated using ANNOVAR software.
11 Based on the FUMA website, we further obtained the eQTL and chromatin
12 interaction annotation results. We selected eQTL datasets from eQTLGen
13 Consortium and five tissue types (i.e., artery tibial, whole blood, and muscle-skeletal)
14 based on the Genotype-Tissue Expression project (GTEx v8), and long-range
15 interactions (Hi-C) dataset from GSE87112 (Mesenchymal stem cell). Additionally,
16 we performed the gene map search in OMIM dataset using '(OSTEOPOROSIS OR
17 "bone fragility" OR "fragile bones" OR "bone mineral density")' to obtain gene list
18 for BMD phenotype. For each physical annotated genes, we collected corresponding
19 evidence codes from the above datasets (p for physical annotation; e for eQTL
20 annotation; h for HiC annotation; o for OMIM results).

21

22 **Integrating polygenic risk score with clinical risk score for risk stratification of** 23 **fracture**

24 *Training, validation, and test datasets*

25 We evaluated the potential clinical utility of polygenic risk scores (PRSs) for
26 fracture incidence combined with traditional clinical risk factors. Here, two training
27 datasets were set in the analyses for DXA-derived BMD (training dataset 1) and heel
28 BMD/fracture (training dataset 2), respectively (**Figure 3A**). The training dataset 1

1 was derived from the aforementioned DXA-derived BMD GWAS. Additionally, all
2 fracture cases (N=35,192) and controls (N=317,599) from the UK biobank were
3 randomly divided into three distinct datasets: training dataset 2 (N=171,459 for
4 controls, N=19,363 for cases), validation (N=73,070 for controls, N=7914 for cases),
5 and test (N=73,070 for controls, N=7915 for cases). These divisions were conducted
6 according to a ratio of 2:1:1. Following this, both heel BMD GWAS and fracture
7 GWAS analyses were performed utilizing the aforementioned GWAS pipeline in
8 training dataset 2 (**Figure 3A**).

9

10 *Generation of polygenic risk scores (PRSs)*

11 Based on GWAS summary statistics from 13 traits (i.e., 11 DXA-derived BMD
12 traits, heel BMD and fracture) in training datasets, we then used the PRSice 2
13 software⁶¹ to implement the clumping and threshold approach for developing PRSs
14 for fracture in the validation dataset (**Figure 3A**). The best predictive PRSs were
15 assessed for transferability and predictivity through the *P*-values and Nagelkerke R^2
16 in logistic model implemented in PRSice 2 software⁶¹, which corrected for age, sex,
17 weight and population stratification (first five principal components). After
18 obtaining the *P*-values threshold for the best predictive PRS from the validation
19 dataset, we calculated the corresponding PRS for each participant in the test dataset
20 (**Figure 3A**).

21

22 *Generation of metaPRS*

23 To generate a combined PRS (i.e., metaPRS), we first removed the 4,248
24 participants with fracture history at the baseline to generate a validation cohort
25 dataset (N=72,648 controls; N=4,088 cases) (**Figure 3A**). Based on this validation
26 cohort dataset, we included all 13 PRSs and conducted stepwise Cox regression in
27 the validation cohort dataset, which could automatically select a reduced number of
28 predictor variables for building the best-performing Cox regression model.

1 Accordingly, we computed the metaPRS by summation of single PRS (which were
2 contained in the best-performing model), weighted by beta value from stepwise Cox
3 regression.

4

5 *Prediction fracture risk*

6 In this analysis, based on test datasets, we further removed the participants with
7 fracture history at the baseline, leaving 76,613 participants as the test cohort datasets
8 for fracture (N=72,629 controls; N=3,984 cases) (**Figure 3A**). We first generated a
9 basic FRAX-BMD model including clinical risk factors from FRAX tools [i.e., sex
10 (categorical: male and female), age (continuous: years), obesity (categorical: 1st,
11 BMI ≤ 20 ; 2nd, $20 < \text{BMI} \leq 25$; 3rd, $25 < \text{BMI} \leq 30$; 4th, $30 < \text{BMI} \leq 35$; 5th, $35 < \text{BMI} \leq 40$; 6th,
12 $40 < \text{BMI} \leq 45$; 7th, BMI > 45), current smoking (categorical: yes and no), current
13 alcohol consumption (categorical: yes and no), and glucocorticoids medicine use
14 (categorical: yes and no)] and heel BMD (**Supplementary Table 21**). Using Cox
15 regression for fracture, we obtained the predicted values based on the basic FRAX-
16 BMD model in the test dataset. We then employed C-statistic as a quantitative
17 measure to evaluate the accuracy of the basic FRAX-BMD model using these
18 predicted values in the same dataset. Additionally, we quantify the variations in
19 discriminative power when integrating various PRSs into the basic FRAX-heel
20 BMD model (FRAX-heel BMD PRS model). Specifically, for each type of PRS (i.e.,
21 heel BMD, 11 DXA-BMD, fracture and metaPRS), we performed a multiple Cox
22 regression for fracture adjusting for age, sex, obesity, smoking, alcohol,
23 glucocorticoids medicine use, heel BMD, and population stratification (the first five
24 principal components). Based on these predicted values, C-statistics and net
25 reclassification improvement (NRI) were used to estimate the improvement in
26 discrimination and reclassification after adding the various PRSs to the basic FRAX-
27 BMD model. The C-statistics change was calculated by $(\text{C-statistics}_{\text{FRAX-heel BMD PRS model}} - \text{C-statistics}_{\text{FRAX-heel BMD model}}) / (\text{C-statistics}_{\text{FRAX-heel BMD model}} - 0.5) * 100\%$. The
28

1 difference of C-statistics from various FRAX-heel BMD PRS models were
2 estimated based on student t-test using *cindex.comp* function from “survomp” R
3 package. The optimal cutoff point, which was obtained from the FRAX-BMD
4 metaPRS model, was utilized to calculate NRI.

5

6 Additionally, to visualize the cumulative incidence of incident fractures across
7 polygenic risk categories (i.e., low (bottom quartile), intermediate (the second to the
8 third quartile), and high (top quartile) polygenic risk categories according to the
9 quintiles of the metaPRS), we employed the “survminer” R package in the test
10 cohorts consisting of time-to-fracture information and corresponding fracture events
11 as well as polygenic risk categories. We also utilized the ‘cuminc’ function to
12 calculate the cumulative incidence curves. Based on the *survfit* function from
13 “survomp” R, we estimated the 10-year absolute fracture risk, and then assessed the
14 interplay of metaPRS and the clinical risk score (from the basic FRAX-heel BMD
15 model) in impacting the risk of fracture.

16

17 **Shared genetic basis of BMD and common chronic diseases**

18 *Genetic correlation and polygenic overlap*

19 In this study, we first estimated the phenotypic correlation between 11 DXA-derived
20 BMD traits (i.e., arms, femur neck, total femur, head, leg, lumbar spine, pelvis, rib,
21 spine, total body and trunk BMD) using spearman correlation. We then supplied the
22 genetic correlation among them using GCTA software, considering the sample
23 overlap. Additionally, we performed linkage disequilibrium score regression
24 (LDSC) analyses⁶², based on 1000 Genomes Project European panel, to assess the
25 genome-wide genetic correlation (r_g) between DXA-BMD and 13 selected common
26 chronic diseases, including neurodegenerative diseases (Alzheimer's disease,
27 Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis)⁶³⁻⁶⁶,
28 cardiovascular diseases (stroke, intracranial aneurysm, atrial fibrillation, coronary

1 artery disease and heart failure)⁶⁷⁻⁷¹ and autoimmune diseases (rheumatoid arthritis,
2 systemic lupus erythematosus and inflammatory bowel diseases)⁷²⁻⁷⁴. For BMD
3 phenotypes with statistically significant genetic correlation, we supplied the
4 bivariate causal mixture model (MiXeR) to quantify the polygenic overlap between
5 BMD and selected chronic diseases beyond genetic correlations²⁹. For a pair of
6 phenotypes, MiXeR estimated the number of trait-influencing SNPs (i.e., SNPs with
7 effects on the disease not inducted by LD) for each trait and the number of shared
8 trait-influencing SNPs based on a bivariate Gaussian mixture model²⁹.

9

10 *Discovery of the shared risk loci*

11 To discover the pleiotropic genetic variants, we performed conditional/conjunctive
12 false discovery rate (condFDR/conjFDR) analysis using genetic summary statistics.
13 We limited our analysis to BMD phenotypes that have evidence to support the
14 shared genetic architecture with common chronic diseases. Based on an empirical
15 Bayesian statistical framework, in the condFDR method, the association between
16 variant and secondary phenotype was used to re-ranks the test statistics and re-
17 calculate the association of this variant with primary phenotype^{75,76}. The conjFDR
18 is determined as the maximum of two condFDR values, which provides a
19 conservative estimate of the posterior probability that a genetic variant showed
20 association with either trait^{75,77}. In this study, the shared genetic variants were
21 defined as variants with conjFDR <0.05. For these identified risk loci with shared
22 effects, we further used the “coloc” R package to determine whether the association
23 signals for DXA-derived BMD and common chronic diseases would co-localize at
24 the shared loci. After extracting genetic association estimates for variants within
25 250kb of the lead SNP, the probability of H4 that the two traits share one causal
26 variant were calculated. The loci with a probability of H4>0.5 were considered to
27 colocalize⁷⁸.

28

1 **Genetic-driven prioritization of drug targets**

2 The therapeutic target lists were obtained from the ChEMBL database (release 29),
3 which curates the drug information from multiple sources (e.g., United States
4 Adopted Name applications, ClinicalTrials.gov, and FDA Orange Book database)⁷⁹.
5 Specifically, based on the targets search results, the proteins with values of activity
6 term ≤ 100 and organisms from homo sapiens remained. Accordingly, a total of
7 3,329 unique druggable genes that encode human target proteins with ENSG ID for
8 approved drugs or clinical candidates were retained in the following analyses
9 (**Supplementary Table 22**).

10

11 We then conducted a series of bioinformatic analyses [i.e., summary-based
12 Mendelian randomization (SMR) and colocalization] to identify prioritized putative
13 druggable genes for BMD treatment. First, we assessed whether the potential
14 genetically regulated expression level of druggable genes were associated with
15 DXA-BMD using SMR⁸⁰. In SMR analyses, the genetic variants were used as
16 instrumental variables to link the outcome (i.e., DXA-BMD) via the exposure of
17 interest (i.e., the expression level of candidate gene). And the instrumental variables
18 were extracted from the cis-eQTLs in three tissues (i.e., muscle, artery tibial, and
19 whole-blood tissues) from GTEx version 8 projects⁸¹ and from eQTLGen
20 consortium (whole blood)⁸². Linkage clumping was conducted based on default
21 protocols. For each DXA-derived BMD phenotype, the SMR results of the
22 druggable genes were retained with false discovery rate (FDR)-corrected
23 significance (FDR-corrected $P_{\text{SMR}} < 0.05$ and $P_{\text{HEIDI}} > 0.05$). Among genes with SMR
24 evidence, we further assessed whether the eQTL and DXA-derived BMD
25 association signals would co-localize at shared loci (i.e., the probability of H4).
26 Specifically, after extracting genetic association estimates of eQTL and DXA-
27 derived BMD traits with variants within 250kb of the lead SNP, colocalization
28 analyses were performed. The genes with a probability of H4 > 0.5 were considered

1 to colocalize ⁷⁸. The drug information of genes with SMR evidence was obtained
2 from the GeneCards website (<https://www.genecards.org>), which collected
3 information from DrugBank, ApexBio, DGIdb, ClinicalTrials.gov, and/or
4 PharmGKB.

5

6 **Acknowledgments**

7 We thank the High-Performance Computing Center at Westlake University for the
8 facility support and technical assistance. This work was supported by China
9 National GeneBank (CNGB) and KingMed Diagnostics, Co., Ltd.

10

11 **Funds**

12 This work was supported by the National Natural Science Foundation of China
13 (#82370887), the "Pioneer" and "Leading Goose" R&D Program of Zhejiang
14 (#2023C03164 and #2024SSYS0032), the Chinese National Key Technology R&D
15 Program, Ministry of Science and Technology (#2021YFC2501702), and the funds
16 from the Westlake Laboratory of Life Sciences and Biomedicine (#202208014).

17

18 **Author contributions**

19 H.-F.Z. conceptualized and designed the study. Y.Q. J.X. and P.G. conducted main
20 analysis. L.H., S.X., G.T., H.Y., G.L., and W.X. contributed additional analysis.
21 Y.Q., J.X., and C.X. drafted the manuscript. C.X., S.K., P.Z., M.Y., J.Z., X.L., J.G.,
22 S.G., X.Y., J.T., X.C., X.C., and M.M. contributed to the interpretation of the data.
23 P.W., G.L., C.Y., M.Q., Y.F., C.Y., G.C., L.X., D.K., Y.X., L.Y., F.H., C.C., and
24 Z.Z. contributed to reviewing and revising the content of the manuscript. All authors
25 reviewed and approved the final manuscript.

26

27 **Declaration of interests**

28 The authors declare no competing interests.

1

2 **Data and code availability**

3 The summary statistics of the present GWASs on 11 DXA-BMD traits and fracture
4 risk were deposited on the WBBC website ^{83,84}
5 (<https://wbbc.westlake.edu.cn/downloads.html>). This study does not report the
6 original code.

1 Reference

- 2 1. Zhu, X., Bai, W. & Zheng, H. Twelve years of GWAS discoveries for
3 osteoporosis and related traits: advances, challenges and applications. *Bone*
4 *Res* **9**, 23 (2021).
- 5 2. Zheng, H.F., Spector, T.D. & Richards, J.B. Insights into the genetics of
6 osteoporosis from recent genome-wide association studies. *Expert Rev Mol*
7 *Med* **13**, e28 (2011).
- 8 3. Salari, N. *et al.* The global prevalence of osteoporosis in the world: a
9 comprehensive systematic review and meta-analysis. *J Orthop Surg Res* **16**,
10 609 (2021).
- 11 4. Guerri, S. *et al.* Quantitative imaging techniques for the assessment of
12 osteoporosis and sarcopenia. *Quant Imaging Med Surg* **8**, 60-85 (2018).
- 13 5. Mullin, B.H. *et al.* Genome-wide association study using family-based
14 cohorts identifies the WLS and CCDC170/ESR1 loci as associated with bone
15 mineral density. *BMC Genomics* **17**, 136 (2016).
- 16 6. Zheng, H.F. *et al.* Meta-analysis of genome-wide studies identifies MEF2C
17 SNPs associated with bone mineral density at forearm. *J Med Genet* **50**, 473-
18 8 (2013).
- 19 7. Estrada, K. *et al.* Genome-wide meta-analysis identifies 56 bone mineral
20 density loci and reveals 14 loci associated with risk of fracture. *Nat Genet* **44**,
21 491-501 (2012).
- 22 8. Zheng, H.F. *et al.* Whole-genome sequencing identifies EN1 as a determinant
23 of bone density and fracture. *Nature* **526**, 112-7 (2015).
- 24 9. Kemp, J.P. *et al.* Identification of 153 new loci associated with heel bone
25 mineral density and functional involvement of GPC6 in osteoporosis. *Nat*
26 *Genet* **49**, 1468-1475 (2017).
- 27 10. Morris, J.A. *et al.* An atlas of genetic influences on osteoporosis in humans
28 and mice. *Nat Genet* **51**, 258-266 (2019).
- 29 11. Lu, T. *et al.* Improved prediction of fracture risk leveraging a genome-wide
30 polygenic risk score. *Genome Med* **13**, 16 (2021).
- 31 12. Lu, T., Forgetta, V., Zhou, S., Richards, J.B. & Greenwood, C.M. Identifying
32 Rare Genetic Determinants for Improved Polygenic Risk Prediction of Bone
33 Mineral Density and Fracture Risk. *J Bone Miner Res* (2023).
- 34 13. Tuna, H. *et al.* Does quantitative tibial ultrasound predict low bone mineral
35 density defined by dual energy X-ray absorptiometry? *Yonsei Med J* **49**, 436-
36 42 (2008).
- 37 14. Xia, J.W. *et al.* Both indirect maternal and direct fetal genetic effects reflect
38 the observational relationship between higher birth weight and lower adult
39 bone mass. *BMC Med* **20**, 361 (2022).
- 40 15. Zhao, P. *et al.* Deciphering the complex relationship between type 2 diabetes
41 and fracture risk with both genetic and observational evidence. *Elife*

- 1 **12**(2024).
- 2 16. He, B. *et al.* Depression and Osteoporosis: A Mendelian Randomization
3 Study. *Calcif Tissue Int* **109**, 675-684 (2021).
- 4 17. Nelson, M.R. *et al.* The support of human genetic evidence for approved
5 drug indications. *Nat Genet* **47**, 856-60 (2015).
- 6 18. Zheng, J. *et al.* Phenome-wide Mendelian randomization mapping the
7 influence of the plasma proteome on complex diseases. *Nat Genet* **52**, 1122-
8 1131 (2020).
- 9 19. Kanis, J.A. *et al.* Case finding for the management of osteoporosis with
10 FRAX--assessment and intervention thresholds for the UK. *Osteoporos Int*
11 **19**, 1395-408 (2008).
- 12 20. Evangelou, E. & Ioannidis, J.P. Meta-analysis methods for genome-wide
13 association studies and beyond. *Nat Rev Genet* **14**, 379-89 (2013).
- 14 21. Lu, Y. *et al.* Classification of osteoporosis based on bone mineral densities. *J*
15 *Bone Miner Res* **16**, 901-10 (2001).
- 16 22. Medina-Gomez, C. *et al.* Bone mineral density loci specific to the skull
17 portray potential pleiotropic effects on craniosynostosis. *Commun Biol* **6**, 691
18 (2023).
- 19 23. Kanis, J.A., Johnell, O., Oden, A., Johansson, H. & McCloskey, E. FRAX
20 and the assessment of fracture probability in men and women from the UK.
21 *Osteoporos Int* **19**, 385-97 (2008).
- 22 24. Bolland, M.J. *et al.* Evaluation of the FRAX and Garvan fracture risk
23 calculators in older women. *J Bone Miner Res* **26**, 420-7 (2011).
- 24 25. Vlak, M.H., Algra, A., Brandenburg, R. & Rinkel, G.J. Prevalence of
25 unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity,
26 country, and time period: a systematic review and meta-analysis. *Lancet*
27 *Neurol* **10**, 626-36 (2011).
- 28 26. Ruigrok, Y.M., Rinkel, G.J. & Wijmenga, C. Genetics of intracranial
29 aneurysms. *Lancet Neurol* **4**, 179-89 (2005).
- 30 27. Alcorta-Sevillano, N., Macias, I., Infante, A. & Rodriguez, C.I. Deciphering
31 the Relevance of Bone ECM Signaling. *Cells* **9**(2020).
- 32 28. Shin, Y.W. *et al.* Association of Bone Mineral Density With the Risk of
33 Intracranial Aneurysm. *JAMA Neurol* **75**, 179-186 (2018).
- 34 29. Frei, O. *et al.* Bivariate causal mixture model quantifies polygenic overlap
35 between complex traits beyond genetic correlation. *Nat Commun* **10**, 2417
36 (2019).
- 37 30. Lopez, I., Mak, E.C., Ding, J., Hamm, H.E. & Lomasney, J.W. A novel
38 bifunctional phospholipase c that is regulated by Galpha 12 and stimulates
39 the Ras/mitogen-activated protein kinase pathway. *J Biol Chem* **276**, 2758-65
40 (2001).
- 41 31. Papaioannou, G., Mirzamohammadi, F. & Kobayashi, T. Ras signaling
42 regulates osteoprogenitor cell proliferation and bone formation. *Cell Death*

- 1 *Dis* **7**, e2405 (2016).
- 2 32. Kouchi, H. *et al.* Manumycin A, inhibitor of ras farnesyltransferase, inhibits
3 proliferation and migration of rat vascular smooth muscle cells. *Biochem*
4 *Biophys Res Commun* **264**, 915-20 (1999).
- 5 33. Cao, G. *et al.* How vascular smooth muscle cell phenotype switching
6 contributes to vascular disease. *Cell Commun Signal* **20**, 180 (2022).
- 7 34. Cheng, W. *et al.* Genetic Association Between Schizophrenia and Cortical
8 Brain Surface Area and Thickness. *JAMA Psychiatry* **78**, 1020-1030 (2021).
- 9 35. Reid, I.R. & Billington, E.O. Drug therapy for osteoporosis in older adults.
10 *Lancet* **399**, 1080-1092 (2022).
- 11 36. Reay, W.R. & Cairns, M.J. Advancing the use of genome-wide association
12 studies for drug repurposing. *Nat Rev Genet* **22**, 658-671 (2021).
- 13 37. Schmidt, A.F. *et al.* Genetic drug target validation using Mendelian
14 randomisation. *Nat Commun* **11**, 3255 (2020).
- 15 38. Holmes, M.V., Richardson, T.G., Ference, B.A., Davies, N.M. & Davey
16 Smith, G. Integrating genomics with biomarkers and therapeutic targets to
17 invigorate cardiovascular drug development. *Nat Rev Cardiol* **18**, 435-453
18 (2021).
- 19 39. Stevenson, J. & medical advisory council of the British Menopause, S.
20 Prevention and treatment of osteoporosis in women. *Post Reprod Health* **29**,
21 11-14 (2023).
- 22 40. Hu, Y., Hu, F.B. & Manson, J.E. Marine Omega-3 Supplementation and
23 Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized
24 Controlled Trials Involving 127 477 Participants. *J Am Heart Assoc* **8**,
25 e013543 (2019).
- 26 41. Qian, F. *et al.* Omega-3 Fatty Acid Biomarkers and Incident Atrial
27 Fibrillation. *J Am Coll Cardiol* **82**, 336-349 (2023).
- 28 42. Gao, J. *et al.* The Effects of n-3 PUFA Supplementation on Bone Metabolism
29 Markers and Body Bone Mineral Density in Adults: A Systematic Review
30 and Meta-Analysis of RCTs. *Nutrients* **15**(2023).
- 31 43. Dou, Y., Wang, Y., Chen, Z., Yu, X. & Ma, D. Effect of n-3 polyunsaturated
32 fatty acid on bone health: A systematic review and meta-analysis of
33 randomized controlled trials. *Food Sci Nutr* **10**, 145-154 (2022).
- 34 44. Hannah, V.C., Ou, J., Luong, A., Goldstein, J.L. & Brown, M.S. Unsaturated
35 fatty acids down-regulate srebp isoforms 1a and 1c by two mechanisms in
36 HEK-293 cells. *J Biol Chem* **276**, 4365-72 (2001).
- 37 45. Hishikawa, D. *et al.* Hepatic Levels of DHA-Containing Phospholipids
38 Instruct SREBP1-Mediated Synthesis and Systemic Delivery of
39 Polyunsaturated Fatty Acids. *iScience* **23**, 101495 (2020).
- 40 46. Shochat, C. *et al.* Deletion of SREBF1, a Functional Bone-Muscle
41 Pleiotropic Gene, Alters Bone Density and Lipid Signaling in Zebrafish.
42 *Endocrinology* **162**(2021).

- 1 47. M., K.A.M.P.G.P.D.S.C.S.E.D.P.L.X.R.T.H.H.G.L. THU0109 Lack of
2 Efficacy of CCR1 Antagonist BMS-817399 in Patients with Moderate to
3 Severe Rheumatoid Arthritis: Results of 12-Week Proof-Of-Concept Study.
4 *Ann Rheum Dis* (2014).
- 5 48. Tak, P.P. *et al.* Chemokine receptor CCR1 antagonist CCX354-C treatment
6 for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical
7 trial. *Ann Rheum Dis* **72**, 337-44 (2013).
- 8 49. Dairaghi, D.J. *et al.* CCR1 blockade reduces tumor burden and osteolysis in
9 vivo in a mouse model of myeloma bone disease. *Blood* **120**, 1449-57 (2012).
- 10 50. Qian, Y. *et al.* Observational and genetic evidence highlight the association
11 of human sleep behaviors with the incidence of fracture. *Commun Biol* **4**,
12 1339 (2021).
- 13 51. Xia, J. *et al.* Systemic evaluation of the relationship between psoriasis,
14 psoriatic arthritis and osteoporosis: observational and Mendelian
15 randomisation study. *Ann Rheum Dis* **79**, 1460-1467 (2020).
- 16 52. Bai, W.Y. *et al.* Identification of PIEZO1 polymorphisms for human bone
17 mineral density. *Bone* **133**, 115247 (2020).
- 18 53. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and
19 genomic data. *Nature* **562**, 203-209 (2018).
- 20 54. Chou, W.C. *et al.* A combined reference panel from the 1000 Genomes and
21 UK10K projects improved rare variant imputation in European and Chinese
22 samples. *Sci Rep* **6**, 39313 (2016).
- 23 55. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-
24 analysis of genomewide association scans. *Bioinformatics* **26**, 2190-2191
25 (2010).
- 26 56. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS
27 summary statistics identifies additional variants influencing complex traits.
28 *Nat Genet* **44**, 369-75, S1-3 (2012).
- 29 57. Medina-Gomez, C. *et al.* Life-Course Genome-wide Association Study
30 Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects.
31 *Am J Hum Genet* **102**, 88-102 (2018).
- 32 58. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of
33 genetic variants from high-throughput sequencing data. *Nucleic Acids Res* **38**,
34 e164 (2010).
- 35 59. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional
36 mapping and annotation of genetic associations with FUMA. *Nat Commun* **8**,
37 1826 (2017).
- 38 60. Amberger, J.S., Bocchini, C.A., Schiettecatte, F., Scott, A.F. & Hamosh, A.
39 OMIM.org: Online Mendelian Inheritance in Man (OMIM(R)), an online
40 catalog of human genes and genetic disorders. *Nucleic Acids Res* **43**, D789-
41 98 (2015).
- 42 61. Choi, S.W. & O'Reilly, P.F. PRSice-2: Polygenic Risk Score software for

- 1 biobank-scale data. *Gigascience* **8**(2019).
- 2 62. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding
3 from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-5
4 (2015).
- 5 63. Jansen, I.E. *et al.* Genome-wide meta-analysis identifies new loci and
6 functional pathways influencing Alzheimer's disease risk. *Nat Genet* **51**, 404-
7 413 (2019).
- 8 64. Nalls, M.A. *et al.* Identification of novel risk loci, causal insights, and
9 heritable risk for Parkinson's disease: a meta-analysis of genome-wide
10 association studies. *Lancet Neurol* **18**, 1091-1102 (2019).
- 11 65. van Rheenen, W. *et al.* Common and rare variant association analyses in
12 amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic
13 architectures and neuron-specific biology. *Nat Genet* **53**, 1636-1648 (2021).
- 14 66. International Multiple Sclerosis Genetics, C. *et al.* Analysis of immune-
15 related loci identifies 48 new susceptibility variants for multiple sclerosis.
16 *Nat Genet* **45**, 1353-60 (2013).
- 17 67. Malik, R. *et al.* Multiancestry genome-wide association study of 520,000
18 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat*
19 *Genet* **50**, 524-537 (2018).
- 20 68. Bakker, M.K. *et al.* Genome-wide association study of intracranial
21 aneurysms identifies 17 risk loci and genetic overlap with clinical risk
22 factors. *Nat Genet* **52**, 1303-1313 (2020).
- 23 69. Nielsen, J.B. *et al.* Biobank-driven genomic discovery yields new insight
24 into atrial fibrillation biology. *Nat Genet* **50**, 1234-1239 (2018).
- 25 70. Nelson, C.P. *et al.* Association analyses based on false discovery rate
26 implicate new loci for coronary artery disease. *Nat Genet* **49**, 1385-1391
27 (2017).
- 28 71. Shah, S. *et al.* Genome-wide association and Mendelian randomisation
29 analysis provide insights into the pathogenesis of heart failure. *Nat Commun*
30 **11**, 163 (2020).
- 31 72. Okada, Y. *et al.* Genetics of rheumatoid arthritis contributes to biology and
32 drug discovery. *Nature* **506**, 376-81 (2014).
- 33 73. Bentham, J. *et al.* Genetic association analyses implicate aberrant regulation
34 of innate and adaptive immunity genes in the pathogenesis of systemic lupus
35 erythematosus. *Nat Genet* **47**, 1457-1464 (2015).
- 36 74. Liu, J.Z. *et al.* Association analyses identify 38 susceptibility loci for
37 inflammatory bowel disease and highlight shared genetic risk across
38 populations. *Nat Genet* **47**, 979-986 (2015).
- 39 75. Andreassen, O.A. *et al.* Improved detection of common variants associated
40 with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk
41 factors. *Am J Hum Genet* **92**, 197-209 (2013).
- 42 76. Schork, A.J., Wang, Y., Thompson, W.K., Dale, A.M. & Andreassen, O.A.

- 1 New statistical approaches exploit the polygenic architecture of
2 schizophrenia--implications for the underlying neurobiology. *Curr Opin*
3 *Neurobiol* **36**, 89-98 (2016).
- 4 77. Smeland, O.B. *et al.* Discovery of shared genomic loci using the conditional
5 false discovery rate approach. *Hum Genet* **139**, 85-94 (2020).
- 6 78. Zhu, Z. *et al.* A genome-wide cross-trait analysis from UK Biobank
7 highlights the shared genetic architecture of asthma and allergic diseases. *Nat*
8 *Genet* **50**, 857-864 (2018).
- 9 79. Mendez, D. *et al.* ChEMBL: towards direct deposition of bioassay data.
10 *Nucleic Acids Res* **47**, D930-D940 (2019).
- 11 80. Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies
12 predicts complex trait gene targets. *Nat Genet* **48**, 481-7 (2016).
- 13 81. Vosa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands
14 of genetic loci and polygenic scores that regulate blood gene expression. *Nat*
15 *Genet* **53**, 1300-1310 (2021).
- 16 82. Consortium, G.T. Human genomics. The Genotype-Tissue Expression
17 (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* **348**,
18 648-60 (2015).
- 19 83. Cong, P.K. *et al.* Genomic analyses of 10,376 individuals in the Westlake
20 BioBank for Chinese (WBBC) pilot project. *Nat Commun* **13**, 2939 (2022).
- 21 84. Zhu, X.W. *et al.* Cohort profile: the Westlake BioBank for Chinese (WBBC)
22 pilot project. *BMJ Open* **11**, e045564 (2021).
- 23
24

1 **Figure legends**

2

3 **Figure 1** Genetic architecture of DXA-BMD at multiple skeletal sites. (A) the
4 skeletal sites of 11 DXA-derived BMD traits and the GWAS study design; (B) the
5 associated genetic loci for DXA-derived BMD and fracture;
6 Abbreviations: DXA, dual-energy X-ray absorptiometry; BMD, bone mineral
7 density; GWAS, genome-wide association study.

8

9 **Figure 2** Forest plot of the genetic association estimates of lead SNPs (A: rs746100;
10 B: rs10840273; C: rs12916774; D: rs6013897; E: rs927059) of novel loci with
11 corresponding BMD traits in female GWASs and male GWASs as well as GWAS
12 meta-analyses of both sexes, along with the result from Mendelian randomization
13 analyses.

14 Abbreviations: BMD, bone mineral density; eQTL, expression quantitative trait
15 locus; IVW, inverse variance weighted; GWAS, genome-wide association study;
16 pQTL, genotype–protein association; SMR, summary-based Mendelian
17 randomization.

18

19 **Figure 3** PRS demonstrated marginal improvement in fracture prediction. (A) study
20 design; (B) Forest plot of the association of each PRS with fracture risk, adjusting
21 for age, sex, obesity, smoking, alcohol, glucocorticoids medicine use, heel BMD,
22 and population stratification (the first five principal components); (C) The fracture
23 predictive results of three models. The FRAX model included clinical risk factors
24 from FRAX tools [i.e., sex, age, obesity, current smoking, current alcohol
25 consumption, and glucocorticoids medicine use]. For the FRAX-heel BMD model,
26 heel BMD was integrated with on the FRAX model. For the FRAX-heel BMD
27 metaPRA model, metaPRS was integrated into the FRAX-heel BMD model; (D)
28 The lifetime and 10-year probability of fracture occurrence across metaPRS
29 categories within each clinical risk strata.

30 Abbreviations: PRS, polygenic risk score

31

32 **Figure 4** The shared genetic architecture of head BMD and intracranial aneurysm.
33 (A) heatmap of genetic and phenotypic correlation between 11 DXA-derived BMD;
34 (B) the genetic correlations of head BMD with 13 common chronic diseases; (C)
35 Venn diagrams of shared variants between head BMD and intracranial aneurysm,
36 and unique variants per trait; (D) Shared loci between head BMD and intracranial
37 aneurysm. Common genetic variants jointly associated with head BMD and
38 intracranial aneurysm at $\text{conjFDR} < 0.05$ were highlighted in red. (E) Forest plot of
39 the genetic association estimates of four joint-associated variants with head BMD
40 and intracranial aneurysm.

41 Abbreviations: BMD, bone mineral density.


42

1 **Figure 5** Prioritization of drug targets. (A) the result of four genes with mendelian
2 randomization evidence. The red downward triangle indicates that genetically
3 predicted expression level of this gene is negatively correlated with BMD, while the
4 blue upward triangle indicates a positive association for BMD; (B) Forest plot of the
5 association of genetically predicted *SREBF1*, *CCR1*, *NCOR1* and *ESR1* gene
6 expression with BMD, based on summary-based mendelian randomization analyses;
7 (C) colocalization results of GWAS and eQTL within *SREBF1*, *CCR1*, *NCOR1* and
8 *ESR1* gene regions; (D) the drug development status of *SREBF1*, *CCR1*, *NCOR1*
9 and *ESR1* genes.
10 Abbreviations: BMD, bone mineral density; eQTL, expression quantitative trait
11 locus; GWAS, genome-wide association study.
12



Table 1 the detailed information on genome-wide association studies of 11 bone mineral density sites.

Phenotype	Sample size	Conditional independent signals			Heritability
		Known	Novel	Total	
Single BMD phenotype					
Head BMD	31986	69	0	69	0.418 (0.045)
Arm BMD	31873	34	0	34	0.321 (0.039)
Femoral neck BMD	32017	36	4	40	0.257 (0.029)
Femur total BMD	31873	41	3	44	0.319 (0.030)
Leg BMD	31873	43	1	44	0.320 (0.034)
Lumbar spine BMD	30449	40	1	41	0.363 (0.034)
Pelvis BMD	31873	48	1	49	0.351 (0.036)
Rib BMD	31873	22	0	22	0.298 (0.030)
Spine BMD	31986	37	0	37	0.353 (0.034)
Total BMD	31986	61	0	61	0.379 (0.039)
Trunk BMD	31873	45	1	46	0.360 (0.036)
All BMD-related phenotypes	\	476 (232 unique)	11 (8 unique)	487 (240 unique)	\
Fracture	352,791 (N=35,192 for cases; N=317,599 for controls)	8	0	8	0.048 (0.007)
Acors phenotypes	\	87	5	92	\

1
2

A

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.18.24301465>; this version posted April 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

**B**

A Lead SNP for loci across 11 BMD trait signals: rs746100, Candidate gene: *ABCA1*

Exposure	Outcome	Method	beta (se)	P-value
Conditional independent SNP: rs1039406 (9:107748958) for allele T	Lumber spine BMD			
	Male (N = 14563)	GWAS	0.041 (0.012)	3.75×10 ⁻⁴
	Female (N = 12964)	GWAS	0.057 (0.012)	5.70×10 ⁻⁶
	sex-combined (N = 27527)	GWAS	0.049 (0.009)	1.21×10 ⁻⁸
Conditional independent SNP: rs746100 (9:107749051) for allele C	Femur neck BMD			
	Male (N = 15349)	GWAS	0.043 (0.011)	1.57×10 ⁻⁴
	Female (N = 13633)	GWAS	0.058 (0.012)	1.77×10 ⁻⁶
	sex-combined (N = 28982)	GWAS	0.050 (0.008)	1.69×10 ⁻⁹
	Femur total BMD			
	Male (N = 15345)	GWAS	0.049 (0.011)	1.74×10 ⁻⁵
	Female (N = 13593)	GWAS	0.052 (0.012)	2.31×10 ⁻⁵
	sex-combined (N = 28938)	GWAS	0.050 (0.008)	1.64×10 ⁻⁹
	Pelvis BMD			
	Male (N = 15314)	GWAS	0.048 (0.011)	2.03×10 ⁻⁵
	Female (N = 13639)	GWAS	0.049 (0.012)	5.67×10 ⁻⁵
	sex-combined (N = 28953)	GWAS	0.049 (0.008)	4.50×10 ⁻⁹
	Trunk BMD			
	Male (N = 15314)	GWAS	0.045 (0.011)	6.22×10 ⁻⁵
	Female (N = 13639)	GWAS	0.050 (0.012)	3.74×10 ⁻⁵
sex-combined (N = 28953)	GWAS	0.048 (0.008)	9.35×10 ⁻⁹	
ABCA1 gene expression in whole blood tissue from eQTLGen	Lumber spine BMD	SMR	0.193 (0.075)	0.010
	Pelvis BMD	SMR	0.185 (0.074)	0.012
	Femur neck BMD	SMR	0.175 (0.073)	0.017
	Femur total BMD	SMR	0.176 (0.074)	0.017

B Lead SNP for loci across 11 BMD trait signals: rs10840273, Candidate gene: *SWAP70*

Exposure	Outcome	Method	beta (se)	P-value
Conditional independent SNP: rs10840273 (11:9642451) for allele T	Leg BMD			
	Male (N = 15326)	GWAS	0.049 (0.012)	2.59×10 ⁻⁵
	Female (N = 13673)	GWAS	0.050 (0.012)	4.44×10 ⁻⁵
	sex-combined (N = 28999)	GWAS	0.050 (0.009)	4.51×10 ⁻⁹
SWAP70 gene expression in whole blood tissue from eQTLGen	Leg BMD	SMR	0.085 (0.030)	4.00×10 ⁻³
	Circulating SWAP70	IVW	0.029 (0.013)	0.027
	Circulating SWAP70	Weighted-median	0.039 (0.027)	0.025

C Lead SNP for loci across 11 BMD trait signals: rs12916774, Candidate gene: *CHSY1*

Exposure	Outcome	Method	beta (se)	P-value
Conditional independent SNP: rs12916774 (15:101710165) for allele A	Femur neck BMD			
	Male (N = 15236)	GWAS	0.063 (0.014)	9.72×10 ⁻⁶
	Female (N = 13523)	GWAS	0.061 (0.015)	6.30×10 ⁻⁵
	sex-combined (N = 28759)	GWAS	0.062 (0.010)	2.44×10 ⁻⁹
Conditional independent SNP: rs11630618 (15:101710434) for allele T	Femur total BMD			
	Male (N = 15227)	GWAS	0.061 (0.014)	1.04×10 ⁻⁵
	Female (N = 13481)	GWAS	0.050 (0.015)	7.25×10 ⁻⁴
	sex-combined (N = 28708)	GWAS	0.056 (0.010)	3.19×10 ⁻⁸


D Lead SNP for loci across 11 BMD trait signals: rs6013897, Candidate gene: *CYP24A1*

Exposure	Outcome	Method	beta (se)	P-value
Conditional independent SNP: rs35194449 (20:52742047) for allele C	Femur total BMD			
	Male (N = 15632)	GWAS	0.069 (0.014)	1.35×10 ⁻⁶
	Female (N = 13848)	GWAS	0.061 (0.015)	5.18×10 ⁻⁵
	sex-combined (N = 29480)	GWAS	0.065 (0.010)	3.10×10 ⁻¹⁰
Conditional independent SNP: rs6013897 (20:52742479) for allele T	Femur neck BMD			
	Male (N = 15670)	GWAS	0.068 (0.014)	1.77×10 ⁻⁶
	Female (N = 13915)	GWAS	0.068 (0.015)	5.96×10 ⁻⁶
	sex-combined (N = 29585)	GWAS	0.068 (0.010)	4.56×10 ⁻¹¹

E Lead SNP for loci across 11 BMD trait signals: rs927059, Candidate gene: *PAX1*

Exposure	Outcome	Method	beta (se)	P-value
Conditional independent SNP: rs927059 (20:21914194) for allele T	Femur neck BMD			
	Male (N = 15651)	GWAS	0.050 (0.011)	9.07×10 ⁻⁶
	Female (N = 13913)	GWAS	0.042 (0.012)	4.89×10 ⁻⁴
	sex-combined (N = 29564)	GWAS	0.047 (0.008)	1.87×10 ⁻⁸
PAX1 gene expression in whole blood tissue from eQTLGen	Femur neck BMD	SMR	0.158 (0.046)	5.33×10 ⁻⁴


A




B






Exposure	HR (95% CI)	P-value
LSBMD PRS	1.031 (1.000-1.064)	0.054
Leg BMD PRS	1.047 (1.015-1.080)	0.005
Rib BMD PRS	1.050 (1.018-1.084)	0.003
Arms BMD PRS	1.052 (1.020-1.086)	0.002
Spine BMD PRS	1.061 (1.028-1.095)	2.81×10 ⁻⁴
Total BMD PRS	1.064 (1.031-1.098)	1.47×10 ⁻⁴
Pelvis BMD PRS	1.066 (1.033-1.100)	9.29×10 ⁻⁵
Head BMD PRS	1.068 (1.035-1.102)	4.33×10 ⁻⁵
FNBMD PRS	1.073 (1.039-1.107)	2.02×10 ⁻⁵
Femur total BMD PRS	1.076 (1.043-1.110)	8.58×10 ⁻⁶
Trunk BMD PRS	1.081 (1.048-1.116)	1.56×10 ⁻⁶
Fracture PRS	1.084 (1.051-1.119)	4.01×10 ⁻⁹
Heel BMD PRS	1.106 (1.070-1.144)	5.65×10 ⁻⁷
MetaPRS	1.134 (1.097-1.173)	4.15×10 ⁻¹⁴

C




D






A: Medelian randomization evidence



C: Colocalization evidence



D: Drug development status

Targets	Drug name	Type	Status
SREBF1	Doconexent	Inhibitor	Approved
SREBF1	Omega-3 fatty acids	Inhibitor	Approved
CCR1	CCX354-C	Inhibitor	Investigational
NCOR1	\	\	\
ESR1	Estradiol	Agonist	Approved

B

Exposure	Outcome	beta(SE)	P-value for SMR	P-value for HEIDI test
SREBF1 expression	Head BMD	-0.157 (0.036)	1.27×10 ⁻⁵	0.293
SREBF1 expression	Total BMD	-0.131 (0.036)	2.57×10 ⁻⁴	0.675
CCR1 expression	Head BMD	-0.079 (0.016)	1.76×10 ⁻⁶	0.094
CCR1 expression	Total BMD	-0.084 (0.016)	3.16×10 ⁻⁷	0.053
NCOR1 expression	Head BMD	0.103 (0.026)	7.99×10 ⁻⁵	0.158
NCOR1 expression	Total BMD	0.109 (0.026)	3.01×10 ⁻⁵	0.458
ESR1 expression	Head BMD	-0.296 (0.070)	2.40×10 ⁻⁵	0.356
ESR1 expression	Leg BMD	-0.586 (0.079)	9.13×10 ⁻¹⁴	0.078
ESR1 expression	Pelvis BMD	-0.556 (0.078)	7.08×10 ⁻¹³	0.052
ESR1 expression	Rib BMD	-0.661 (0.081)	4.94×10 ⁻¹⁶	0.150
ESR1 expression	Spine BMD	-0.686 (0.082)	8.98×10 ⁻¹⁷	0.095
ESR1 expression	Total BMD	-0.638 (0.081)	2.34×10 ⁻¹⁵	0.060
ESR1 expression	Trunk BMD	-0.674 (0.082)	1.93×10 ⁻¹⁶	0.056
ESR1 expression	Femur total BMD	-0.457 (0.074)	7.53×10 ⁻¹⁰	0.108
ESR1 expression	Femur neck BMD	-0.405 (0.073)	2.55×10 ⁻⁸	0.200